Hepatitis C, Chronic — Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV
Citation(s)
Phase 2B, Partially Blinded, Randomized Study in Treatment Naive HCV G1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron Plus Ribavirin Given Bi-weekly in Comparison With PEG-Intron Plus Ribavirin Given Weekly